Dane L Shiltz (Dane Shiltz)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Interstitial Lung Disease

Candida Albicans

Rheumatoid Arthritis Patients

Top Venues

SAGE open medicine

The Annals of pharmacotherapy

Expert review of pharmacoeconomics & outcomes research

This page only lists publications with an associated author ORCID identifier.

Publications

Kayla Berry, Laura Postlmayr, Dane L Shiltz, Jessi Parker, Calvin Ice
Impact of an inpatient pharmacist-driven renal dosing policy on order verification time and patient safety. SAGE open medicine 12 (2024)
Kayla Berry, Laura Postlmayr, Dane L Shiltz, Jessi Parker, Calvin Ice
Impact of an inpatient pharmacist-driven renal dosing policy on order verification time and patient safety. SAGE open medicine 12 (2024)
Qian Ding, Dane L Shiltz, Dana Hossami, Alison M Konieczny
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States. Expert review of pharmacoeconomics & outcomes research 22 (8) (2022)
Aleah R Hunt, Shawn N Coffeen, Dane L Shiltz, Calvin Ice, Jessi Parker
Factor VIII Inhibitor Bypassing Activity (FEIBA) Reversal for Apixaban and Rivaroxaban in Patients With Acute Intracranial and Nonintracranial Hemorrhage. The Annals of pharmacotherapy 55 (12) (2021)